2-chloro 7-cyano bicyclo[4.2.0]1,3,5-octatriene | 103447-24-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 2-chloro 7-cyano bicyclo[4.2.0]1,3,5-octatriene
• 英文别名: 3-chloro-1-cyanobenzocyclobutane；3-chloro-1,2-dihydrocyclobutabenzene-1-carbonitrile；2-Chlorobicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile；2-chlorobicyclo[4.2.0]octa-1(6),2,4-triene-7-carbonitrile
• CAS: 103447-24-1
• 化学式: C₉H₆ClN
• 分子量: 163.606
• InChiKey: BFRUJEXHNIKCMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloro 7-cyano bicyclo[4.2.0]1,3,5-octatriene 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.5h， 以90%的产率得到2-chlorobicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid
  参考文献：
  名称：

  Synthesis of hexahydro[2]benzopyrano[4,3-c]pyridines as serotonin 5-HT2C receptor agonists via intramolecular hetero Diels–Alder reactions

  摘要：

  Hexahydro[2]benzopyrano[4,3-c]pyridines were synthesized by an intramolecular hetero Diels-Alder reaction. The reaction was applicable to a range of substrates and the products could be easily converted into serotonin 5-HT2C receptor agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.03.054
• 作为产物：
  描述：

  3-(2,6-dichlorophenyl)propanenitrile 生成 2-chloro 7-cyano bicyclo[4.2.0]1,3,5-octatriene
  参考文献：
  名称：

  Bicyclo (4.2.0) 1,3,5-octatriene compounds and use as .alpha.-adrenergics

  摘要：

  公式为：##STR1## 其中：R.sub.1和R.sub.2各自独立地代表氢、卤素、烷基或具有1至4个碳原子的烷氧基，磺酰胺可能被1至4个碳原子的烷基基团取代；或者一起成为亚甲二氧基，n为0或1，为外消旋或光学异构体形式，以及它们与药学上可接受的酸的加成盐。在治疗与肾上腺素受体相关的疾病和/或病症方面有用，这种关系在艺术中是众所周知的。

  公开号：

  US04567181A1

文献信息

• [EN] TRICYCLIC HETEROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES TRICYCLIQUES
  申请人：ORGANON NV

  公开号：WO2009037220A1

  公开（公告）日：2009-03-26

  The present invention relates to a tricyclic heterocyclic derivative of Formula (I) wherein the variables are as defined in the specification. The present invention further relates to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular for the treatment of serotonin-mediated disorders such as obesity, schizophrenia and cognitive dysfunction.

  本发明涉及式(I)所示的三环杂环衍生物，其中变量如说明书中所定义。本发明进一步涉及包含这些化合物的药物组合物及其在治疗中的应用，特别是用于治疗由血清素介导的疾病，如肥胖、精神分裂症和认知功能障碍。
• Benzocyclobutane compounds
  申请人：Adir et Compagnie

  公开号：US06107345A1

  公开（公告）日：2000-08-22

  A compound of formula (I): ##STR1## wherein: Z.sub.1, Z.sub.2, Z.sub.3, Z.sub.4, which may be identical or different, represent a group as defined in the description, X represents oxygen, S(O).sub.p, --(CH.sub.2).sub.n -- or --CH.sub.2 --Y--CH.sub.2 -- wherein p, n and Y are as defined in the description, A represents ##STR2## wherein m, R.sub.1, R.sub.2 and G are as defined in the description, their isomers and addition salts thereof with a pharmaceutically-acceptable acid, and medicinal products containing the same are useful in the treatment of diseases like depression, panic attacks, obsessive compulsive disorders, phobias, impulsive disorders, drug abuse or anxiety.

  式(I)的化合物：其中：Z₁，Z₂，Z₃，Z₄，可以相同也可以不同，表示如描述中定义的基团，X表示氧、S(O)ₚ、--(CH₂)ₙ--或--CH₂--Y--CH₂--其中p，n和Y如描述中定义，A表示其中m，R₁，R₂和G如描述中定义，它们的异构体及其与药用可接受的酸的加合盐，以及含有它们的药物产品在治疗抑郁症、恐慌发作、强迫性障碍、恐惧症、冲动障碍、药物滥用或焦虑等疾病方面是有用的。
• Bicyclo (4.2.0) 1,3,5-octatriene compounds and use as .alpha.-adrenergics
  申请人：ADIR, s.a.r.l.

  公开号：US04567181A1

  公开（公告）日：1986-01-28

  Compounds of the formula: ##STR1## in which: R.sub.1 and R.sub.2 each represent, independently of one another, hydrogen, halogen, alkyl or alkoxy having from 1 to 4 carbon atoms, sulphonamide possibly substituted by an alkyl radical having from 1 to 4 carbon atoms; or together methylenedioxy, n is 0 or 1, in racemic form or in the form of optical isomers, and also their salts of addition with pharmaceutically acceptable acids. Useful in the treatment of ailments and/or conditions which are adrenoreceptor-related, such relationship being well known in the art.

  公式为：##STR1## 其中：R.sub.1和R.sub.2各自独立地代表氢、卤素、烷基或具有1至4个碳原子的烷氧基，磺酰胺可能被1至4个碳原子的烷基基团取代；或者一起成为亚甲二氧基，n为0或1，为外消旋或光学异构体形式，以及它们与药学上可接受的酸的加成盐。在治疗与肾上腺素受体相关的疾病和/或病症方面有用，这种关系在艺术中是众所周知的。
• 1,2-benzisoxazole compounds
  申请人：Adir et Compagnie

  公开号：US05100902A1

  公开（公告）日：1992-03-31

  Compounds of formula I ##STR1## in which m represents an integer from 0 to 5, n represents an integer from 1 to 2, p is equal to 0, 1 or 2, X, Y and Z, which may be identical or different, each represent a hydrogen atom, a halogen atom, a linear or branched alkyl radical, a trifluoromethyl radical, an alkoxy radical, an alkylthio radical or a hydroxyl radical, and R represents a 2-benzofuranyl or 2,3-dihydro-2-benzofuranyl radical (it being possible for each to be substituted on the benzene ring), a 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-2-yl radical, a 4-oxo-4H-chromen-2-yl radical (optionally substituted on the benzene ring), a benzocyclobutenyl radical of formula A or an indanyl radical of formula B: ##STR2## (in which: R.sub.1 and R.sub.2, which may be identical or different, each represent a hydrogen atom, a halogen atom, a trifluoromethyl radical, an alkyl radical, an alkoxy radical, a hydroxyl radical, a hydroxyalkyl radical or an alkylthio radical, or together form a methylenedioxy radical or an ethylenedioxy radical, and R.sub.3 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms), or a radical of formula C: ##STR3## (in which R.sub.4, R.sub.5 and R.sub.6, which may be identical or different, each represent a hydrogen atom, a halogen atom, a trifluoromethyl radical, a hydroxyl radical, an alkyl radical, an alkoxy radical or an alkylthio radical, their optical isomers and their addition salts with a pharmaceutically acceptable organic or inorganic acid.

  式I的化合物##STR1##，其中m表示0到5的整数，n表示1到2的整数，p等于0、1或2，X、Y和Z可以相同也可以不同，分别表示氢原子、卤素原子、线性或支链烷基、三氟甲基基、烷氧基、烷基硫基或羟基基团，而R表示2-苯并呋喃基或2,3-二氢-2-苯并呋喃基（每个基团都可能在苯环上取代）、4-氧代-4H-香豆素-2-基基团（在苯环上可选择性取代）、式A的苯环戊二烯基基团或式B的茚基基团：##STR2##（其中：R.sub.1和R.sub.2，可以相同也可以不同，分别表示氢原子、卤素原子、三氟甲基基团、烷基、烷氧基、羟基、羟基烷基或烷基硫基，或者一起形成甲二氧基基团或乙二氧基基团，而R.sub.3表示氢原子或具有1到6个碳原子的线性或支链烷基基团），或式C的基团：##STR3##（其中R.sub.4、R.sub.5和R.sub.6，可以相同也可以不同，分别表示氢原子、卤素原子、三氟甲基基团、羟基基团、烷基、烷氧基或烷基硫基团，它们的光学异构体和其与药学上可接受的有机或无机酸的加成盐）。
• Tricyclic heterocyclic derivatives
  申请人：Davies Keneth

  公开号：US08729274B2

  公开（公告）日：2014-05-20

  The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.

  本发明涉及一种三环杂环衍生物，其符合公式（I）中定义的变量，或其药学上可接受的盐或溶剂。本发明还涉及包含所述三环杂环衍生物的制药组合物，并且它们在治疗中的应用，例如用于治疗或预防由血清素介导的疾病，如肥胖症。